A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential
Velasco-Hernandez, T.; Trincado, J. L.; Vinyoles, M.; Closa, A.; Gutierrez-Aguera, F.; Molina, O.; Rodriguez-Cortez, V. C.; Petazzi, P.; Beneyto-Calabuig, S.; Velten, L.; Romecin, P.; Casquero, R.; Abollo-Jimenez, F.; Diaz de la Guardia, R.; Lorden, P.; Bataller, A.; Lapillonne, H.; Stam, R. W.; Vives, S.; Torrebadell, M.; Fuster, J. L.; Bueno, C.; Eyras, E.; Heyn, H.; Menendez, P.
Show abstract
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML), and is driven by rare therapy-resistant leukemia-initiating stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling keeps cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to AML-LSC function and chemoresistance and is a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we provide a comprehensive single-cell expression atlas (119,000 cells) of AML cells and AML-LSCs in paired diagnostic-relapse samples from risk-stratified patients with AML. The HIF/hypoxia pathway is attenuated in AML-LSCs compared with differentiated AML cells, but is enhanced when compared with healthy hematopoietic cells. Accordingly, chemical inhibition cooperates with standard-of-care chemotherapy to impair leukemogenesis, substantially eliminating AML-LSCs. These findings support the HIF pathway as a stem cell regulator in human AML, and reveal avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy 99%
- Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia 98%
- Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia 98%
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 98%
- Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties 97%
- A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis 97%
Similar papers in this journal
Similar papers in this journal
- N-MYC regulates Cell Survival via eIF4G1 in inv(16) Acute Myeloid Leukemia 96%
- Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers 95%
- TCF3::HLF Orchestrates an Enhancer-Promoter Network with Activation of MEF2C to Promote Immature HSC gene Expression in Leukemia 94%
Similar papers in this journal
- Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells 98%
- Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth 97%
- Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.